Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, and the stock tumbles

Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer’s.

Source: MarketWatch

Continue reading...